Applicant: Masayuki Tsuchiya et al. Attorney's Docket No.: 14875-0151US1 / C1-A0305P-US

Serial No.: 10/550,934 Filed: August 25, 2006

Page : 2 of 12

Amendment to the Specification:

At page 10, please replace the paragraph beginning at line 5 with the following:

When using vectors to produce the antibodies of this invention, expression vectors are particularly useful. When an expression vector is expressed in *E. coli*, for example, it should have the above characteristics in order to be amplified in *E. coli*. Additionally, when *E. coli* such as JM109, DH5α, HB101, or XL1-Blue are used as the host cell, the vector preferably has a promoter, for example, a lacZ promoter (Ward *et al.* (1989) Nature 341:544-546; (1992) FASEB J. 6:2422-2427), araB promoter (Better *et al.* (1988) Science 240:1041-1043), or T7 promoter, to allow efficient expression of the desired gene in *E. coli*. Other examples of the vectors include pGEX-5X-1 (Pharmacia), "QIAexpress system" QIAEXPRESS® vector system (QIAGEN), pEGFP, and pET (where BL21, a strain expressing T7 RNA polymerase, is preferably used as the host).